RxDoctor Payments Data

Stacey Shelton

Nurse Practitioner · Jacksonville, FLNPI 1609284983

Payments from drug & device makers

$5,885in general payments, 2019–2025

Across 329 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$713
  • Novo Nordisk$625
  • AbbVie$526
  • AstraZeneca$463
  • Boehringer Ingelheim$303
  • GSK$250
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$5,885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,885 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$46,183
Medicare patients
173
Services billed
1,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$35,009
JanumetSitagliptin Phos/Metformin Hcl11$12,149
TrulicityDulaglutide12$11,574
RybelsusSemaglutide11$10,595
SymbicortBudesonide/Formoterol Fumarate11$2,450
Rosuvastatin Calcium170$1,595
Atorvastatin Calcium159$1,465
Omeprazole76$1,311
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,194
Fluticasone Propionate71$1,070
Gabapentin55$1,062
SynthroidLevothyroxine Sodium13$936
Levothyroxine Sodium88$860
Amlodipine Besylate171$788
Albuterol Sulfate HfaAlbuterol Sulfate28$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$625$45,60450 claims
MerckJanumet$147$12,14911 claims
Lilly USA, LLCTrulicity$713$11,57412 claims
AstraZenecaSymbicort$463$2,45011 claims
AbbVieSynthroid$526$93613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$52$86088 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →